After nearly 15 years on the market, AstraZeneca’s popular “purple pill,” Nexium, will face generic competition. Teva Pharmaceuticals, an Israeli generics manufacturer with American headquarters in ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

LONDON (MarketWatch) - AstraZeneca shares lost ground Tuesday after the Anglo-Swedish pharmaceutical said an Indian drugmaker is looking to make a copy of its Nexium heartburn drug.

Biopharmaceutical company AstraZeneca has agreed to pay $425 million to settle product liability suits over two heartburn drugs, Prilosec and Nexium, according to an Oct. 3 news release. The ...

Drugs giant AstraZeneca has agreed to settle a raft of legal claims over its heartburn treatments for 425 million US dollars (£352 million). The FTSE 100 listed firm said the agreements will ...

Pharmaceutical company AstraZeneca said Tuesday it will pay $425 million to settle lawsuits from people who experienced kidney damage from the company’s heartburn medications Nexium and Prilosec.

(RTTNews) - British drug major AstraZeneca Plc (AZN.L, AZN) announced Tuesday that it has entered into settlement agreements in the product liability litigations related to Nexium and Prilosec.

(RTTNews) - British drug major AstraZeneca Plc (AZN.L, AZN) announced Tuesday that it has entered into settlement agreements in the product liability litigations related to Nexium and Prilosec ...

AstraZeneca will pay $425 million to settle lawsuits on behalf of consumers who suffered kidney injuries while using its heartburn medications Nexium and Prilosec. AstraZeneca in a statement said ...